Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 335 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial... September 25, 2024 Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... April 1, 2021 Receiving a Blood Transfusion During Cancer: What to Know and What... October 19, 2023 Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life September 30, 2021 Load more HOT NEWS How clues from crystals might help us prevent the overtreatment of... Cancer in My Community: Addressing Health Disparities in Brazil FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma Washington Farmers Harvest Crops For Neighbor With Stage Four Cancer
